close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 2,072 trials Clear all
Filter by:

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Acute Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
    Acute Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
  • Phase Phase 3
    Phase 3
INTERVENTION

Procedure: Hematopoietic stem cells transplantation

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Procedure: Hematopoietic stem cells transplantation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Institut Paoli-Calmettes, Marseille, France

Brief Summary

This study is an extension to younger patients of the currently ongoing national, multicenter, open-label, randomized phase III HAPLOMUDELDERLY which evaluates elderly patients with hematological malignancies, justifying an allo-HSCT from an alternative donor when a MRD has not been identified. It will extend the investigation of these two modalities of allo-HSCT to younger patients which are eligible to RIC.

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

  • Status Active, not recruiting
    Active, not recruiting
  • Condition SARS-CoV-2 Infection, COVID-19, Moderate and Severe COVID-19
    SARS-CoV-2 Infection, COVID-19, Moderate and Severe COVID-19
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Other: Standard of Care (SoC), Drug: Remdesivir

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Other: Standard of Care (SoC), Drug: Remdesivir

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Gesundheit Nord gGmbH, Bremen, Germany

Brief Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.

The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute Myocardial Infarction (RECONSIDER)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition ST-segment Elevation Myocardial Infarction, Left Ventricular Remo...
    ST-segment Elevation Myocardial Infarction, Left Ventricular Remo...
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: Hydrocortisone, Drug: Placebo

Eligibility
  • Ages: 18 to 85 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Hydrocortisone, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

"Niculae Stancioiu" Heart Institute, Cluj-Napoca, Cluj, Romania

Brief Summary

Introduction: In the setting of acute ST-segment elevation myocardial infarction (STEMI) coronary wedge pressure (CWP) emerges as a new marker for the advanced form of pre-procedural microvascular obstruction (MVO), which is associated with inflammatory interstitial edema. Through its anti-inflammatory effects, glucocorticoid therapy may prove beneficial in patients with high CWP. Aim: To identify the presence of the advanced form of MVO before primary percutaneous coronary intervention (PPCI) by CWP measurement and to test the benefit of cortisol therapy, in terms of infarct size and left ventricular remodeling, in patients with raised CWP. Methods: 50 patients with a first STEMI, candidates for PPCI, with proximal coronary occlusion, will undergo CWP measurement followed by percutaneous revascularization. Cardiac MRI will be performed 3-5 days after the procedure. A cutoff for CWP in predicting MVO, interstitial oedema and intramyocardial haemorrhage will be derived.Based on the above mentioned cutoff, 180 patients with continuous elevation of the pressure line will be randomized, by a 1:1 model, either to cortisol therapy or to placebo. Inflammatory parameters will be determined from peripheral blood samples. Patients will undergo cardiac magnetic resonance (CMR) imaging 3 to 5 days after revascularization. Study endpoints: The primary endpoint will be the extent of MVO, interstitial edema and hemorrhage. Secondary endpoints will include infarct size, myocardial salvage, left ventricular volumes and ejection fraction. The clinical endpoints of all-cause and cardiovascular death, myocardial re-infarction, target vessel revascularization, stent thrombosis and stroke will be recorded at 6 months.

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Diabetic Foot Ulcer
    Diabetic Foot Ulcer
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: ALLO-ASC-DFU, Procedure: Vehicle sheet

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: ALLO-ASC-DFU, Procedure: Vehicle sheet

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Korea University Kuro Hospital, Seoul, Korea, Republic of

Brief Summary

This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to placebo therapy.

Effect of Baricitinib Treatment on Peripheral Bone in RA

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Rheumatoid Arthritis, Bone Density, Finger Joints
    Rheumatoid Arthritis, Bone Density, Finger Joints
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Baricitinib

Eligibility
  • Ages: 18 to 74 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Baricitinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Universitiy Hospital Erlangen, Erlangen, Bavaria, Germany

Brief Summary

Patients with Rheumatoid Arthritis (RA) suffer systemic and peripheral bone loss. In this study we aim to test the efficacy of in-label treatment with Baricitinib on the volumetric bone mineral density in patients with RA over 52 weeks. Inclusion of RA patients comprises pathologic volumetric bone mineral density measured by (High Resolution peripheral quantitative Computed Tomomgraphy) HR-pQCT maging of finger joints.

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Sars-CoV2, COVID-19
    Sars-CoV2, COVID-19
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Favipiravir (3200 mg + 1200 mg), Drug: Favipiravir (3600 mg + 1600 mg), Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine, Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine combined with Azithromycin

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Favipiravir (3200 mg + 1200 mg), Drug: Favipiravir (3600 mg + 1600 mg), Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine, Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine combined with Azithromycin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hacettepe University, School of Medicine, Ankara, Turkey

Brief Summary

This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19, Viral Respiratory Illnesses
    COVID-19, Viral Respiratory Illnesses
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex

Eligibility
  • Ages: 18 to 120 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

HealthStar Research LLC, Hot Springs, Arkansas, United States

Brief Summary

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Phase 3
    Phase 3
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.

Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Nasopharyngeal Carcinoma
    Nasopharyngeal Carcinoma
  • Phase Phase 3
    Phase 3
INTERVENTION

Radiation: Loco-regional Radiotherapy

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Radiation: Loco-regional Radiotherapy

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Brief Summary

This is a randomized parallel control trial to evaluate whether radical loco-regional Radiotherapy can prolong survival time of initial untreated metastatic nasopharyngeal carcinoma.

Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Infections, Coronavirus
    Infections, Coronavirus
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: azoximer bromide, Other: Placebo

Eligibility
  • Ages: 18 to 85 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: azoximer bromide, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Regional state budgetary institution of public health "City hospital No. 5 of Barnaul", Barnaul, Russian Federation

Brief Summary

The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIbIIIa clinical trial.